Estrogen-blocking drugs could offer mortality benefit for women with elevated breast cancer risk

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive Cancer Center and colleagues showed that these treatments could also reduce the risk of dying from the disease in women who are at high risk.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login